About
Trellis Bioscience develops human-derived monoclonal antibody therapeutics targeting bacterial, viral infectious diseases, and cancer using its proprietary CellSpot technology platform.
Explore Trellis Bioscience's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.